# A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors

> **NCT05240898** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 116 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** RO7623066
- **DRUG:** Olaparib
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT05240898
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-26
- **Primary completion:** 2025-11-26
- **Final completion:** 2025-11-26
- **Target enrollment:** 116 (ACTUAL)
- **Last updated:** 2025-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05240898

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05240898, "A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05240898. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*